Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans

Gothenburg, February 10, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the company will participate in the scientific conference International Society for Cell & Gene Therapy (ISCT) Meeting 2025 in New Orleans, USA, taking place from May 7 to May 10. At the conference, the company will present initial data from the ongoing clinical Phase I/IIa CARMA study, which show complete tumor remission in the first patient one month after treatment.

Margareth Jorvid, regulatory expert and board member of Elicera Therapeutics, will participate in a networking session to present the company's scientific poster titled "iTANK Platform-Derived CAR20(NAP)-T Cell For Lymphoma: Complete Remission Data Reported For First Patient."

"We are pleased to have recently presented successful data from the ongoing clinical Phase I/IIa CARMA study, where the first patient achieved complete tumor remission one month after treatment. Since the patients treated in CARMA are severely ill and are only included in our study when no other treatment options remain, such positive data is, of course, particularly emotional. Provided that patient enrollment progresses according to the study timeline, we also hope to present consolidated data from the first patient cohort at ISCT 2025," says Jamal El-Mosleh, CEO of Elicera Therapeutics.

ISCT brings together leading researchers, clinicians, and industry experts in cell and gene therapy from around the world. The primary goal of the conference is to facilitate the exchange of new scientific advancements, technological innovations, and clinical insights in the rapidly evolving field of cell and gene therapy.

For more information: https://www.isctglobal.org/annual-meeting/homepage